2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T619,Of 653 participants enrolled, 323 were randomized in MVOR-1 (247 [76.5%] women; mean [SD] age, 47.2 [13.7] years) and 330 were randomized in MVOR-2 (249 [75.5%] women; mean [SD] age, 51.6 [14.0] years). DFD-29 demonstrated superior efficacy in IGA success rates compared with placebo (MVOR-1: treatment difference [TD], 32.9%; 95% CI, 19.6-46.2; P < .001; MVOR-2: TD, 34.1%; 95% CI, 21.3-46.8; P < .001) and compared with doxycycline (MVOR-1: TD, 18.0%; 95% CI, 5.0-31.1; P = .01; MVOR-2: TD, 28.3%; 95% CI, 17.4-39.3; P < .001). DFD-29 also showed superior efficacy in least-squares mean reductions in total inflammatory lesions vs placebo (MVOR-1: TD, -9.2; 95% CI, -11.5 to -6.9; P < .001; MVOR-2: TD, -6.8; 95% CI, -8.9 to -4.8; P < .001) and doxycycline (MVOR-1: TD, -4.7; 95% CI, -6.7 to -2.8; P < .001; MVOR-2: TD, -3.5; 95% CI, -5.4 to -1.6; P < .001). Adverse events with DFD-29, doxycycline, and placebo were reported in 32 of 121 (26.4%), 25 of 116 (21.6%), and 27 of 76 (35.5%), respectively, in MVOR-1 and 51 of 122 (41.8%), 40 of 121 (33.1%), and 30 of 82 (36.6%), respectively, in MVOR-2. The most common adverse events with DFD-29, doxycycline, and placebo were nasopharyngitis, reported in 4 of 121 (3.3%), 2 of 116 (1.7%), and 3 of 76 (3.9%), respectively, in MVOR-1 and 13 of 122 (10.7%), 10 of 121 (8.3%), and 13 of 82 (15.9%), respectively, in MVOR-2, and COVID-19, reported in 4 of 121 (3.3%), 3 of 116 (2.6%), and 4 of 76 (5.3%) in MVOR-1 and 7 of 122 (5.7%), 8 of 121 (6.6%), and 5 of 82 (6.1%) in MVOR-2.31:Tb0f,A low-dose modified formulation of minocycline hydrochloride, DFD-29, is under evaluation for treating papulopustular rosacea (PPR). To determine the efficacy and safety of DFD-29, 40 mg, compared with doxycycline, 40 mg, and placebo for treating PPR. This study included data from 2 double-blind, placebo-controlled, phase 3 randomized clinical trials (MVOR-1 and MVOR-2) conducted between March 2022 and May 2023 at 61 centers in the US and Germany. Healthy adults 18 years and older with moderate to severe PPR were included. Participants were randomized 3:3:2 to oral DFD-29 (minocycline hydrochloride capsules), 40 mg; doxycycline, 40 mg; or placebo once daily for 16 weeks. The coprimary efficacy outcomes were (1) proportion of participants with Investigator's Global Assessment (IGA) treatment success with DFD-29 vs placebo and (2) total inflammatory lesion count reductions with DFD-29 vs placebo. Secondary outcomes included comparisons between DFD-29 and doxycycline in coprimary outcomes and between DFD-29 and placebo in erythema reduction. Of 653 participants enrolled, 323 were randomized in MVOR-1 (247 [76.5%] women; mean [SD] age, 47.2 [13.7] years) and 330 were randomized in MVOR-2 (249 [75.5%] women; mean [SD] age, 51.6 [14.0] years). DFD-29 demonstrated superior efficacy in IGA success rates compared with placebo (MVOR-1: treatment difference [TD], 32.9%; 95% CI, 19.6-46.2; P < .001; MVOR-2: TD, 34.1%; 95% CI, 21.3-46.8; P < .001) and compared with doxycycline (MVOR-1: TD, 18.0%; 95% CI, 5.0-31.1; P = .01; MVOR-2: TD, 28.3%; 95% CI, 17.4-39.3; P < .001). DFD-29 also showed superior efficacy in least-squares mean reductions in total inflammatory lesions vs placebo (MVOR-1: TD, -9.2; 95% CI, -11.5 to -6.9; P < .001; MVOR-2: TD, -6.8; 95% CI, -8.9 to -4.8; P < .001) and doxycycline (MVOR-1: TD, -4.7; 95% CI, -6.7 to -2.8; P < .001; MVOR-2: TD, -3.5; 95% CI, -5.4 to -1.6; P < .001). Adverse events with DFD-29, doxycycline, and placebo were reported in 32 of 121 (26.4%), 25 of 116 (21.6%), and 27 of 76 (35.5%), respectively, in MVOR-1 and 51 of 122 (41.8%), 40 of 121 (33.1%), and 30 of 82 (36.6%), respectively, in MVOR-2. The most common adverse events with DFD-29, doxycycline, and placebo were nasopharyngitis, reported in 4 of 121 (3.3%), 2 of 116 (1.7%), and 3 of 76 (3.9%), respectively, in MVOR-1 and 13 of 122 (10.7%), 10 of 121 (8.3%), and 13 of 82 (15.9%), respectively, in MVOR-2, and COVID-19, reported in 4 of 121 (3.3%), 3 of 116 (2.6%), and 4 of 76 (5.3%) in MVOR-1 and 7 of 122 (5.7%), 8 of 121 (6.6%), and 5 of 82 (6.1%) in MVOR-2. In this study, DFD-29 was superior in efficacy to both doxycycline and placebo and demonstrated a favorable risk-benefit profile in the treatment of PPR. ClinicalTrials.gov Identifiers: NCT05296629 and NCT05343455.32:Tffd,IntroductionA low-dose modified formulation of minocycline hydrochloride, DFD-29, is under evaluation for treating papulopustular rosacea (PPR).ObjectiveTo determine the efficacy and safety of DFD-29, 40 mg, compared with doxycycline, 40 mg, and placebo for treating PPR.Design, Setting, and ParticipantsThis study included data from 2 double-blind, placebo-controlled, phase 3 randomized clinical trials (MVOR-1 and MVOR-2) conducted between March 2022 and May 2023 at 61 centers in the US and Germany. Healthy adults 18 years and older with moderate to severe PPR were included.InterventionsParticipants were randomized 3:3:2 to oral DFD-29 (minocycline hydrochloride capsules), 40 mg; doxycycline, 40 mg; or placebo once daily for 16 weeks.Main Outcomes and MeasuresThe coprimary efficacy outcomes were (1) proportion of participants with Investigator’s Global Assessment (IGA) treatment success with DFD-29 vs placebo and (2) total inflammatory lesion count reductions with DFD-29 vs placebo. Secondary outcomes included comparisons between DFD-29 and doxycycline in coprimary outcomes and between DFD-29 and placebo in erythema reduction.ResultsOf 653 participants enrolled, 323 were randomized in MVOR-1 (247 [76.5%] women; mean [SD] age, 47.2 [13.7] years) and 330 were randomized in MVOR-2 (249 [75.5%] women; mean [SD] age, 51.6 [14.0] years). DFD-29 demonstrated superior efficacy in IGA success rates compared with placebo (MVOR-1: treatment difference [TD], 32.9%; 95% CI, 19.6-46.2; P &lt; .001; MVOR-2: TD, 34.1%; 95% CI, 21.3-46.8; P &lt; .001) and compared with doxycycline (MVOR-1: TD, 18.0%; 95% CI, 5.0-31.1; P = .01; MVOR-2: TD, 28.3%; 95% CI, 17.4-39.3; P &lt; .001). DFD-29 also showed superior efficacy in least-squares mean reductions in total inflammatory lesions vs placebo (MVOR-1: TD, −9.2; 95% CI, −11.5 to −6.9; P &lt; .001; MVOR-2: TD, −6.8; 95% CI, −8.9 to −4.8; P &lt; .001) and doxycycline (MVOR-1: TD, −4.7; 95% CI, −6.7 to −2.8; P &lt; .001; MVOR-2: TD, −3.5; 95% CI, −5.4 to −1.6; P &lt; .001). Adverse events with DFD-29, doxycycline, and placebo were reported in 32 of 121 (26.4%), 25 of 116 (21.6%), and 27 of 76 (35.5%), respectively, in MVOR-1 and 51 of 122 (41.8%), 40 of 121 (33.1%), and 30 of 82 (36.6%), respectively, in MVOR-2. The most common adverse events with DFD-29, doxycycline, and placebo were nasopharyngitis, reported in 4 of 121 (3.3%), 2 of 116 (1.7%), and 3 of 76 (3.9%), respectively, in MVOR-1 and 13 of 122 (10.7%), 10 of 121 (8.3%), and 13 of 82 (15.9%), respectively, in MVOR-2, and COVID-19, reported in 4 of 121 (3.3%), 3 of 116 (2.6%), and 4 of 76 (5.3%) in MVOR-1 and 7 of 122 (5.7%), 8 of 121 (6.6%), and 5 of 82 (6.1%) in MVOR-2.Conclusions and RelevanceIn this study, DFD-29 was superior in efficacy to both doxycycline and placebo and demonstrated a favorable risk-benefit profile in the treatment of PPR.Trial RegistrationClinicalTrials.gov Identifiers: NCT05296629 and NCT0534345525:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Papulopustular Rosacea: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Papulopustular Rosacea (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Papulopustular%20Rosacea\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Papulopustular Rosacea\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Papulopustular%20Rosacea\"}]}}"}}]],["$","$L2f",null,{"title":"Papulopustular Rosacea: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Papulopustular Rosacea with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1001/jamadermatol.2024.6542","pmid":"40042869","title":"Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-03-05T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2024.6542","source_score":75,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-06-16","doi":"10.1001/jamadermatol.2024.6542","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"75","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.6542","title":"Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"40042869","conclusions":"","publication_date":"2025-03-05T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.6542","URL":"https://doi.org/10.1001/jamadermatol.2024.6542","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2830693/jamadermatology_bhatia_2025_oi_240074_1747728352.5315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"499","type":"journal-article","issue":"5","score":1,"title":["Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea"],"author":[{"given":"Neal","family":"Bhatia","sequence":"first","affiliation":[{"name":"Therapeutics Clinical Research, San Diego, California"}]},{"given":"James","family":"Del Rosso","sequence":"additional","affiliation":[{"name":"JDR Dermatology Research, Las Vegas, Nevada"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[{"name":"Henry Ford Health System, Detroit, Michigan"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[{"name":"Sanova Dermatology, Austin, Texas"}]},{"given":"Zoe Diana","family":"Draelos","sequence":"additional","affiliation":[{"name":"Dermatology Consulting Services, High Point, North Carolina"}]},{"given":"Srinivas","family":"Sidgiddi","sequence":"additional","affiliation":[{"name":"Journey Medical Corporation, Scottsdale, Arizona"}]},{"given":null,"family":null,"sequence":"additional","affiliation":[]},{"given":"Kenneth W.","family":"Dawes","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Sunil S.","family":"Dhawan","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Rosalyn Elizabeth","family":"George","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Cheryl A.","family":"Hull","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Robert S.","family":"Haber","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Jeffrey","family":"Adelglass","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Javier","family":"Alonso-Llamazares","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Mark","family":"Amster","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Francisco L.","family":"Badar","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Sureka","family":"Bollepalli","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Steven A.","family":"Davis","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Oscar","family":"De Valle","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"James Q.","family":"Del Rosso","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Zoe Diana","family":"Draelos","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"David","family":"Fivenson","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"David L.","family":"Fried","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Terry M.","family":"Jones","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Steven E","family":"Kempers","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Francisco A.","family":"Kerdel","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Michael H.","family":"Gold","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Pinkas E.","family":"Lebovits","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Neal D.","family":"Bhatia","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Mark S.","family":"Lee","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Mark A.","family":"McCune","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Steven K.","family":"Grekin","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Walter K.","family":"Nahm","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Jorge L.","family":"Santander","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Stephen M.","family":"Schleicher","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Javier F.","family":"Chang","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Matthew L.","family":"Miller","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Leonardo M.","family":"Allende","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Eddie","family":"Armas","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Megan Poynot","family":"Couvillion","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Jess J.","family":"DeMaria","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Francisco","family":"Flores","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Theresa Greene","family":"Knoepp","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Edward L.","family":"Lain","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Megan B.","family":"Vissing","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Douglas K.","family":"Logan","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Cindy E.","family":"Owen","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Melody Lynn","family":"Stone","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Janet C.","family":"DuBois","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Diane E.","family":"Vargas","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Hector","family":"Wiltz","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Paul Steven","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Scott T.","family":"Guenthner","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Cheryl","family":"Burgess","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Thomas","family":"Dirschka","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Johannes","family":"Niesmann","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Jens","family":"Rossbacher","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Sebastian","family":"Zimmer","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Swarna","family":"Ekanayake-Bohlig","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Rolf","family":"Dominicus","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Oliver","family":"Weirich","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Beate","family":"Schwarz","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Tanja C.","family":"Fischer","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Harald","family":"Brüning","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Beatrice","family":"Gerlach","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Udo","family":"Amann","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]}],"issued":{"date-parts":[[2025,5,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-03-05T16:02:49Z","timestamp":1741190569000,"date-parts":[[2025,3,5]]},"indexed":{"date-time":"2025-09-03T10:55:32Z","timestamp":1756896932318,"date-parts":[[2025,9,3]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2830693"}},"subtitle":["Two Phase 3 Randomized Clinical Trials"],"deposited":{"date-time":"2025-05-21T15:00:31Z","timestamp":1747839631000,"date-parts":[[2025,5,21]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,5,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1111/bjd.16481","key":"doi240074r1","year":"2018","issue":"2","author":"Gether","volume":"179","first-page":"282","unstructured":null,"article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r2","year":"2015","issue":"3","author":"Oge’","volume":"92","first-page":"187","unstructured":null,"article-title":"Rosacea: diagnosis and treatment.","journal-title":"Am Fam Physician","doi-asserted-by":null},{"DOI":"10.1111/bjd.18420","key":"doi240074r3","year":"2020","issue":"5","author":"Schaller","volume":"182","first-page":"1269","unstructured":null,"article-title":"Recommendations for rosacea diagnosis, classification and management: update from the Global Rosacea Consensus 2019 Panel.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r4","year":"2015","issue":"4","author":"van Zuuren","volume":null,"first-page":null,"unstructured":null,"article-title":"Interventions for rosacea.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":null,"key":"doi240074r5","year":"2019","issue":"6","author":"Del Rosso","volume":"12","first-page":"17","unstructured":null,"article-title":"Update on the management of rosacea from the American Acne & Rosacea Society (AARS).","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"doi240074r6","year":"2013","issue":"6","author":"Del Rosso","volume":"92","first-page":"277","unstructured":null,"article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents.","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.2340/0001555572178179","key":"doi240074r7","year":"1992","issue":"3","author":"Akamatsu","volume":"72","first-page":"178","unstructured":null,"article-title":"Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1902/jop.2008.080051","key":"doi240074r8","year":"2008","issue":"9","author":"Cazalis","volume":"79","first-page":"1762","unstructured":null,"article-title":"Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models.","journal-title":"J Periodontol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.phrs.2010.10.004","key":"doi240074r9","year":"2011","issue":"2","author":"Griffin","volume":"63","first-page":"102","unstructured":null,"article-title":"Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action.","journal-title":"Pharmacol Res","doi-asserted-by":"publisher"},{"DOI":"10.4049/jimmunol.176.1.567","key":"doi240074r10","year":"2006","issue":"1","author":"Hoyt","volume":"176","first-page":"567","unstructured":null,"article-title":"Doxycycline modulates nitric oxide production in murine lung epithelial cells.","journal-title":"J Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1128/AAC.01540-08","key":"doi240074r11","year":"2009","issue":"5","author":"Ishikawa","volume":"53","first-page":"1760","unstructured":null,"article-title":"Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.","journal-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r12","year":"1998","issue":"9","author":"Pruzanski","volume":"25","first-page":"1807","unstructured":null,"article-title":"Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2.","journal-title":"J Rheumatol","doi-asserted-by":null},{"DOI":"10.2174/0929867013373598","key":"doi240074r13","year":"2001","issue":"3","author":"Ryan","volume":"8","first-page":"305","unstructured":null,"article-title":"Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity.","journal-title":"Curr Med Chem","doi-asserted-by":"publisher"},{"DOI":"10.1016/0266-4356(94)90137-6","key":"doi240074r14","year":"1994","issue":"2","author":"Ueyama","volume":"32","first-page":"96","unstructured":null,"article-title":"Effects of antibiotics on human polymorphonuclear leukocyte chemotaxis in vitro.","journal-title":"Br J Oral Maxillofac Surg","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r16","year":"2006","issue":"3","author":"Del Rosso","volume":"77","first-page":"153","unstructured":null,"article-title":"Clinical significance of brand versus generic formulations: focus on oral minocycline.","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1002/14651858.CD002086.pub2","key":"doi240074r17","year":"2012","issue":"8","author":"Garner","volume":"2012","first-page":null,"unstructured":null,"article-title":"Minocycline for acne vulgaris: efficacy and safety.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.3390/antibiotics10070757","key":"doi240074r18","year":"2021","issue":"7","author":"Martins","volume":"10","first-page":"757","unstructured":null,"article-title":"A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea.","journal-title":"Antibiotics (Basel)","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r20","year":"2021","issue":"12","author":"Tsianakas","volume":"14","first-page":"16","unstructured":null,"article-title":"Minocycline extended-release comparison with doxycycline for the treatment of rosacea: a randomized, head-to-head, clinical trial.","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1001/jama.2013.281053","key":"doi240074r21","year":"2013","issue":"20","author":"World Medical Association","volume":"310","first-page":"2191","unstructured":null,"article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.05.044","key":"doi240074r22","year":"2014","issue":"4","author":"Tan","volume":"71","first-page":"760","unstructured":null,"article-title":"Reliability of Clinician Erythema Assessment grading scale.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2006.11.021","key":"doi240074r23","year":"2007","issue":"5","author":"Del Rosso","volume":"56","first-page":"791","unstructured":null,"article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2015.12.037","key":"doi240074r24","year":"2016","issue":"5","author":"Zaenglein","volume":"74","first-page":"945","unstructured":null,"article-title":"Guidelines of care for the management of acne vulgaris.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r25","year":"2014","issue":"3","author":"Fiscus","volume":"4","first-page":null,"unstructured":null,"article-title":"Minocycline-induced hyperpigmentation.","journal-title":"J Community Hosp Intern Med Perspect","doi-asserted-by":null},{"DOI":"10.1159/000017852","key":"doi240074r26","year":"1998","issue":"1","author":"Chosidow","volume":"196","first-page":"162","unstructured":null,"article-title":"Comedonal diffusion of minocycline in acne.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r27","year":"2021","issue":"8","author":"Del Rosso","volume":"14","first-page":"14","unstructured":null,"article-title":"Nonantibiotic properties of tetracyclines in rosacea and their clinical implications.","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1111/bph.12139","key":"doi240074r28","year":"2013","issue":"2","author":"Garrido-Mesa","volume":"169","first-page":"337","unstructured":null,"article-title":"Minocycline: far beyond an antibiotic.","journal-title":"Br J Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00011-016-0999-x","key":"doi240074r29","year":"2017","issue":"2","author":"Parenti","volume":"66","first-page":"107","unstructured":null,"article-title":"Minocycline affects human neutrophil respiratory burst and transendothelial migration.","journal-title":"Inflamm Res","doi-asserted-by":"publisher"},{"DOI":"10.1093/jac/48.suppl_1.5","key":"doi240074r30","year":"2001","issue":null,"author":"Andrews","volume":"48","first-page":"5","unstructured":null,"article-title":"Determination of minimum inhibitory concentrations.","journal-title":"J Antimicrob Chemother","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r31","year":"2007","issue":"6","author":"Fowler","volume":"6","first-page":"641","unstructured":null,"article-title":"Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1046/j.1365-2133.2001.03956.x","key":"doi240074r32","year":"2001","issue":"2","author":"Ross","volume":"144","first-page":"339","unstructured":null,"article-title":"Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1086/598510","key":"doi240074r33","year":"2009","issue":"10","author":"Schwartz","volume":"48","first-page":"1483","unstructured":null,"article-title":"Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300.","journal-title":"Clin Infect Dis","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-016-0380-z","key":"doi240074r34","year":"2016","issue":"9","author":"Steinhoff","volume":"33","first-page":"1481","unstructured":null,"article-title":"Topical ivermectin 10 mg/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments.","journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":"10.1126/scitranslmed.abd8077","key":"doi240074r36","year":"2021","issue":"625","author":"Jo","volume":"13","first-page":null,"unstructured":null,"article-title":"Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.","journal-title":"Sci Transl Med","doi-asserted-by":"publisher"},{"DOI":"10.1902/jop.2000.71.9.1472","key":"doi240074r37","year":"2000","issue":"9","author":"Thomas","volume":"71","first-page":"1472","unstructured":null,"article-title":"Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility.","journal-title":"J Periodontol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r35","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240074r15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Oracea. Prescribing information. Galderma Laboratories; 2022. Accessed February 6, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050805s002lbl.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240074r19","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Minocin. Prescribing information. Triax Pharmaceuticals; 2010. Accessed February 5, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050649023lbl.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,5,1]]},"reference-count":37,"published-online":null,"references-count":37,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamadermatol.2024.6542","is_oa":false,"title":"Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea","updated":"2025-08-04T14:10:34+00:00","published_date":"2025-03-05","best_oa_location":null}},"created_at":"2025-09-19T18:40:43.237Z","updated_at":"2025-09-19T18:49:32.880Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"condition","value":"Papulopustular Rosacea","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"generic","value":"minocycline","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"modality","value":"Tetracycline Antibiotic","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"sample_size","value":"n=653","value_numeric":653},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"warning","value":"Absolute IGA success rates and baseline lesion counts are not reported; only treatment differences and least-squares mean changes are provided.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"warning","value":"Findings are pooled across two separate phase 3 RCTs when summarizing effects.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"warning","value":"Outcomes are reported over 16 weeks; longer-term efficacy and safety are not described in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Two phase 3, double-blind randomized trials (MVOR-1 and MVOR-2) tested oral DFD-29 (minocycline HCl) 40 mg once daily vs doxycycline 40 mg and placebo for 16 weeks in adults with moderate to severe papulopustular rosacea.","key_result":"DFD-29 increased IGA treatment success vs placebo by 32.9% (95% CI, 19.6–46.2) and 34.1% (21.3–46.8) and vs doxycycline by 18.0% (5.0–31.1) and 28.3% (17.4–39.3), all P≤.01. It reduced total inflammatory lesions vs placebo by LS mean −9.2 and −6.8 and vs doxycycline by −4.7 and −3.5; adverse events occurred in 32/121 (26.4%) and 51/122 (41.8%) on DFD-29 vs 25/116 (21.6%) and 40/121 (33.1%) on doxycycline and 27/76 (35.5%) and 30/82 (36.6%) on placebo.","practice_takeaway":"In adults with moderate to severe papulopustular rosacea, 16 weeks of DFD-29 40 mg daily outperformed doxycycline 40 mg and placebo on IGA success and lesion reduction, with no excess adverse events in these trials."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Papulopustular Rosacea"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Papulopustular Rosacea"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Papulopustular Rosacea"}}}]]

Papers